Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
about
Efficacy and tolerability of amifostine in elderly cancer patientsConcurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity.Acute adaptive immune response correlates with late radiation-induced pulmonary fibrosis in mice.Clarithromycin Attenuates Radiation-Induced Lung Injury in Mice.Induction of MiR-21 by Stereotactic Body Radiotherapy Contributes to the Pulmonary Fibrotic Response.A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapyDosimetric analysis of radiation-induced gastric bleedingFactors predicting radiation pneumonitis in locally advanced non-small cell lung cancerGastrointestinal radiation injury: symptoms, risk factors and mechanismsRadiation dose-volume effects in the esophagusManagement of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.Choice of radiotherapy planning modality influences toxicity in the treatment of locally advanced esophageal cancer.Combination of radiotherapy and chemotherapy in locally advanced NSCLC.Lung adenocarcinoma: lessons in translation from bench to bedside.Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs--threshold doses for tissue reactions in a radiation protection context.Radioprotectants to reduce the risk of radiation-induced carcinogenesis.A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer: Results of NRG Oncology RTOG 1012.Pulmonary toxicity generated from radiotherapeutic treatment of thoracic malignancies.Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung CancerSurvey of Policies and Guidelines on Antioxidant Use for Cancer Prevention, Treatment, and Survivorship in North American Cancer Centers: What Do Institutions Perceive as Evidence?Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study.The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor beta1 and tumor necrosis factor alpha.Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels.Lycopene in the Prevention of Radiation-Induced Esophagitis.Therapy monitoring using dynamic MRI: analysis of lung motion and intrathoracic tumor mobility before and after radiotherapy.[Effect of amifostine on locally advanced non-small cell lung cancer patients treated with radiotherapy: a meta-analysis of randomized controlled trials].Amifostine- and chemoradiotherapy-related esophagitis in small cell lung cancer: a single institutional series and literature update
P2860
Q33738758-437C0BCC-74FD-4F31-B3A7-A538F4D9BBB8Q34785152-CF34E8FB-90F4-4789-9677-7D0A06AE008DQ35010640-749270B1-07F2-427D-886B-C846284CA530Q35125702-0FFB53F0-D719-4169-A964-254EBC6E8F18Q35675409-5DB099FB-2EB3-4A65-9F78-DCF3DDC9CB75Q36015400-82F4E187-A6A9-4F76-A514-EEE040D37F5BQ36059005-5FE72C9F-139D-4624-B5ED-12DCB2BD5220Q36177088-F4A3EF97-CDBA-4222-B9EB-48CFA815C86AQ36195977-0AEF5AAD-F7A2-4343-AC7F-80C6BFDC40C0Q36541173-FE5E0991-E871-4612-818F-22EAA1DB1C33Q36655289-CD8981B7-0C93-4C06-9DCC-6948E132B6C4Q36811458-3D853607-2E8E-4818-8D40-7C0FE3AAFECDQ36823982-036A6E76-62B4-4B71-A26D-896377FAD00FQ37466258-857BA458-4E7F-4648-8633-DDEADB0B1C0EQ37614572-0D25F818-905D-400C-825A-EF33FB3B4488Q37812063-06A7134F-0710-45FE-BC7A-09592BC9D780Q38019401-5C419FC5-A1FC-4968-9B7C-E5C5B6C1990DQ38038330-8FA2A118-F2E0-4E60-A0EB-D2625749EE8AQ38155924-6740B954-C288-4141-9221-992C5B242F8CQ38937757-D4593452-B65A-404B-924E-93CBBE83EAFBQ39426003-9EC6733E-B93B-497D-9B88-83D7DD9A2EE1Q41670890-710B4D72-4678-492B-8130-B46284112588Q43429878-CAB2E7EE-95F0-4EDA-BE83-0D16412E6385Q44661107-5F086A85-595D-48B5-89C3-1D7C36A62339Q45918068-B67F60AE-24C1-4153-92A9-6E6C171CD1C0Q46452016-84941983-2622-4754-96A1-85942C3C41C9Q47342475-5E2806B4-3DDE-4AFF-94BA-31FE3E1C1300Q52802045-A2733A8F-4D3D-4746-98E5-DD9B9CE25CD6Q53626507-33BD44CC-0964-4FB8-90B3-2EE60931C88BQ55429590-061FCF05-3162-434D-97EC-4E79ACAE1973Q58754674-27E26FE8-BDC1-4EB4-AC57-B98F48B32522
P2860
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Randomized phase III trial of ...... th advanced-stage lung cancer.
@en
Randomized phase III trial of ...... th advanced-stage lung cancer.
@nl
type
label
Randomized phase III trial of ...... th advanced-stage lung cancer.
@en
Randomized phase III trial of ...... th advanced-stage lung cancer.
@nl
prefLabel
Randomized phase III trial of ...... th advanced-stage lung cancer.
@en
Randomized phase III trial of ...... th advanced-stage lung cancer.
@nl
P2093
P1476
Randomized phase III trial of ...... th advanced-stage lung cancer.
@en
P2093
Clinical Radiation Oncololgy Hellenic Group
D Antonadou
G Georgakopoulos
H Athanassiou
K Panoussaki
M Synodinou
N Coliarakis
N Throuvalas
P304
P356
10.1016/S0360-3016(01)01713-8
P407
P577
2001-11-01T00:00:00Z